In:
Sarcoma, Wiley, Vol. 2020 ( 2020-04-01), p. 1-15
Abstract:
Soft tissue sarcomas (STS) are a highly heterogeneous group of cancers of mesenchymal origin with diverse morphologies and clinical behaviors. While surgical resection is the standard treatment for primary STS, advanced and metastatic STS patients are not eligible for surgery. Systemic treatments, including standard chemotherapy and newer chemical agents, still play the most relevant role in the management of the disease. Discovery of specific genetic alterations in distinct STS subtypes allowed better understanding of mechanisms driving their pathogenesis and treatment optimization. This review focuses on the available targeted drugs or drug combinations based on genetic aberration involved in STS development including chromosomal translocations, oncogenic mutations, gene amplifications, and their perspectives in STS treatment. Furthermore, in this review, we discuss the possible use of chemotherapy sensitivity and resistance assays (CSRA) for the adjustment of treatment for individual patients. In summary, current trends in personalized management of advanced and metastatic STS are based on combination of both genetic testing and CSRA.
Type of Medium:
Online Resource
ISSN:
1357-714X
,
1369-1643
DOI:
10.1155/2020/6716742
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
1338527-6
detail.hit.zdb_id:
2011839-9
